Skip to main content

Roser Ferrer Costa

I'm the Head of Clinical Biochemistry Service at Hospital's Clinical Laboratories and co-chief of Clinical Biochemistry Group, Pharmaceutical Vehiculation and VHIR Research Therapy. I lead a team of professionals in clinical biochemistry, developing care, teaching and research, with a project towards the highest excellence. I am a PhD in Biomedicine for UB, a specialist in the area of knowledge of clinical biochemistry of hormones and a master's degree in Health Institutions Management and currently an Associate Professor of the UAB.

Institutions of which they are part

Head of group
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Head of Department
Bioquímica
Cross-departmental services

Roser Ferrer Costa

Institutions of which they are part

Head of group
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Head of Department
Bioquímica
Cross-departmental services

I'm the Head of Clinical Biochemistry Service at Hospital's Clinical Laboratories and co-chief of Clinical Biochemistry Group, Pharmaceutical Vehiculation and VHIR Research Therapy. I lead a team of professionals in clinical biochemistry, developing care, teaching and research, with a project towards the highest excellence. I am a PhD in Biomedicine for UB, a specialist in the area of knowledge of clinical biochemistry of hormones and a master's degree in Health Institutions Management and currently an Associate Professor of the UAB.

Healthcare activity:
Since 2007 I have been working at the University Hospital, where I trained as a specialist in Clinical Biochemistry (2003). I am a trained pharmacist and until 2019 I was responsible for the Hormone Process (Endocrin Pathology) of the same Service and later Head of Section of the Automated Laboratory. Since 2023, I have been Head of Clinical Biochemistry Service.

The Clinical Biochemistry Service is part of the Clinical Laboratories of the Vall d'Hebron University Hospital, which also provides coverage for the entire population, with pubic health care, of the city of Barcelona (1.5 million people).
In 2019 I completed my master's degree in Health Institutions Management, I have training in healthcare processes and specialisation in automation, concepts that I try to apply in my usual practice and in the Service. Finally, I am the secretary of the hospital's In Vitro Diagnostic Commission.

Research activity:
I am a Doctor of Biomedicine from the University of Barcelona (2015) and co-chief of Clinical Biochemistry Group, Vehiculation of Pharmacists and Therapy Research from the Research Institute of the Vall d'Hebron University Hospital since 2023. In recent years I have been actively involved in different publications of the Service itself and in collaboration with research groups and hospital services.
Attached to the eCore Personalized Medicine, Innovative Diagnostics, Molecular Imaging . Digital Health of VHIR.
I am president of the Catalan Clinical Laboratory Science Association (since June 2021) and member of the Hormone Commission (since 2011) and of the Executive Committee (since 2018) of the Spanish Society of Medicine of the Laboratory (SEQCML).

Docent Activity:
I am currently Associate Professor of the Autonomous University of the Department of Biochemistry and Molecular Biology, Medicine Biochemistry Unit.
I am participating in the postgraduate doctoral thesis management of the Biochemistry Service.

Research lines

Determinación de hormonas con alta sensibilidad

IP: Roser Ferrer Costa, Marina Giralt Arnaiz

Laboratory management and automatitzation

IP: Ernesto Casis Saenz, Roser Ferrer Costa, Clara Ramírez Serra

Anàlisi de dades massives (big data), explotació de dades i mostres als Laboratoris Clínics

IP: Roser Ferrer Costa

Projects

Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT)

IP: Abasolo Olaortua, Ibane
Collaborators: Arranz Amo, José Antonio, Barquin Del Pino , Raquel , Laura Conesa Milian, Clara Ramírez Serra, Yolanda Villena Ortiz, Joan López Hellin, Albert Blanco Grau, Francisco Rodríguez Frias, Roser Ferrer Costa, Joaquin Seras Franzoso, Diego Baranda Martínez-Abasca, Laura Castillo Ribelles, Clara Carnicer Cáceres, Marina Giralt Arnaiz, Ana Gomez Garcia, Simon Schwartz Navarro, Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT), Pablo Gabriel Medina, Rosanna Paciucci Barzanti, Zamira Vanessa Diaz Riascos, Marc Miquel Moltó Abad, Laura Castellote Bellés, Daniel Bravo Nieto, Luz María Cruz Carlos, Clara Sanz Gea, Alba Estela García Fernández, Maria del Pilar Reimundo Diaz-Fierros, Belen Garcia Prats, Noelia Díaz Troyano, JAUME VIMA BOFARULL, Pacín Ruíz, Beatriz, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Cortese , Maria Francesca
Funding agency: AGAUR no fer servir-correcte 4301-37
Funding: 60000
Reference: 2021 SGR 01173
Duration: 01/01/2022 - 31/12/2024

COVID-19, PERFIL INMUNOLÓGICO DE RIESGO

IP: Pujol Borrell, Ricardo
Collaborators: Hernández González, Manuel, Martínez Gallo, Mónica, Labrador Horrillo, Moisés, Codina Grau, Gema, Albert Blanco Grau, Antón Pagarolas, Andres, Álvarez Fernandez, Antonio, Fernández Hidalgo, Nuria, Roser Ferrer Costa, Esteve Ribera Pascuet, Ruiz Rodriguez, Juan Carlos, Ferrer Sancho, Jaume, Suy Franch, Anna, Soler Palacín, Pere, Selva O'Callaghan, Albert, Pumarola Suñé, Tomàs, Ruiz Camps, Isabel, Miarons Font , Marta, Alvarez De la Sierra, Daniel, Martín Nalda, Andrea, Polverino , Eva, Romina Dieli Crimi, Dieli Crimi, Romina
Funding agency: Instituto de Salud Carlos III
Funding: 229000
Reference: COV20/00416
Duration: 08/05/2020 - 08/11/2021

RECEPTORES INHBITORIOS (NEGATIVE IMMUNE CHECKPOINT RECEPTORS, NCRs) EN AUTOINMUNIDAD TIROIDEA Y CANCER, NUEVAS VÍAS TERAPÉUTICAS EN AUTOINMUNIDAD

IP: Pujol Borrell, Ricardo
Collaborators: González López, Oscar, Roser Ferrer Costa, Carmela Iglesias i Felip, Ana María Marín Sánchez, Casteras Román, Anna, Garralda Cabanas, Elena, Alvarez De la Sierra, Daniel
Funding agency: Instituto de Salud Carlos III
Funding: 147620
Reference: PI17/00324
Duration: 01/01/2018 - 30/06/2022

PAPEL DEL RECEPTOR DE TSH EN LOS TIMOCITOS EN EL INICIO DE LA ENFERMEDAD DE GRAVES (EG) Y MECANISMOS DE TIROIDITIS

IP: Pujol Borrell, Ricardo
Collaborators: González López, Oscar, Roser Ferrer Costa, Gabriel Obiols Alfonso, Ana María Marín Sánchez, Isabel Caragol Urgelles, Casteras Román, Anna, Fernandez Doblas, Joaquin
Funding agency: Instituto de Salud Carlos III
Funding: 80465
Reference: PI14/00848
Duration: 01/01/2015 - 31/12/2018

Related news

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

During the last year, the collaboration between Vall d’Hebron and ZeClinics has found three nanobody candidates with potent anticancer properties in zebrafish model.

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.

Related professionals

Javier  Gonzalez Campos

Javier Gonzalez Campos

Tècnic/a Grau Superior
IT / Information Systems
Digital Transformation and Quality Area
Read more
Laia Pinos  Tella

Laia Pinos Tella

Epidemiology and Public Health
Read more
Esther Puig Rodriguez

Esther Puig Rodriguez

Medium Grade Technician
Tenders and Procurement Unit
Finances Area
Read more
Pere Barba Suñol

Pere Barba Suñol

Main researcher
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.